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Cytokine-mediated immunity is crucial in the defense against pathogens. Recently, IL-23 and IL-27 were identiﬁed, which along
with IL-12 belong to the IL-12 cytokine family. IL-27 is pivotal for the induction of helper T cell (Th) 1 responses while IL-23 is
important for the proliferation of memory type Th1 cells. Recent studies revealed that IL-27 also has an anti-inﬂammatory prop-
erty. In some protozoan infection, various proinﬂammatory cytokines were over produced causing lethal inﬂammatory responses
in IL-27 receptor-deﬁcient mice. The anti-inﬂammatory eﬀect of IL-27 depends, at least partly, on inhibition of the development
of Th17 cells, a newly identiﬁed Th population that is induced by IL-23 and is characterized by the production of the inﬂammato-
genic cytokine, IL-17. IL-27 thus has a double identity as an initiator and as an attenuator of immune responses and inﬂammation.
With the discoveries of the new IL-12-related cytokines and Th17 cells, Th development is facing a new paradigm.
Copyright © 2007 Hiroki Yoshida et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Immune responses against pathogens determine the course
of infection as well as the pathogenesis of diseases caused by
the pathogens. During the responses, immune cells, such as
dendritic cells, macrophages, and T and B lymphocytes, are
orchestrated by various cytokines produced by the immune
cells themselves. For instance, during infections with some
protozoa, such as Leishmania major or Trypanosoma cruzi,
the importance of IFN-γ has been proven not only experi-
mentally but also clinically [1, 2]. IFN-γ is produced mainly
by helper T cell (Th) 1-diﬀerentiated CD4+ T cells, a popu-
lation induced by IL-12, although other types of cells, such
as NK/NKT cells and CD8+ T cells are also known to pro-
duce IFN-γ. While being critically important for the defense
against pathogens, cytokines are sometimes notorious as
causative agents for the development of immunopathology
and inﬂammation, which may result in organ/tissue dam-
age. TNF-α, a cytokine produced by Th1-type CD4+ Tc e l l s
and activated macrophages for defense against intracellular
pathogens, may induce cell apoptosis or necrosis depend-
ing on situation. Therefore, it is essential that one should
mount proper immune responses against pathogens, making
sure the response is not too weak to eliminate pathogens or
too strong to damage the host. Recently, two new cytokines,
IL-23 and IL-27 have been identiﬁed as members of the IL-
12cytokinefamily.WithIL-12,acytokineknownasthemost
potent Th1-inducing cytokine, the IL-12 cytokine family has
been shown to be involved in various diseases such as infec-
tion, autoimmune diseases, and inﬂammations. This review
will focus on the complicated roles of IL-27, as well as those
of related cytokines, and their potential importance during
some protozoan infections.
2. Th1 DIFFERENTIATION AND IL-12
CYTOKINE FAMILY
When stimulated through T-cell receptors, CD4+ Tc e ll sp r o -
liferate and diﬀerentiate into either Th1 or Th2 cells, two
functionally distinct subsets that produce characteristic cy-
tokines, respectively [3]. Th1 cytokines, especially IFN-γ,
are critical for the macrophage activation and nitric oxide
production required for eliminating intracellular pathogens
such as L. major [4]. In contrast, Th2 cytokines such as IL-
4, IL-5, and IL-13 are important for inducing humoral im-
munity required to expel helminth from the digestive canal
[5]. Th1 and Th2 cells develop from the same Th precur-
sor (Thp or Th0) cells, but which subset diﬀerentiates in a
given situation is driven by factors, particularly cytokines, in
the surrounding microenvironment. IL-12 promotes IFN-γ2 Journal of Biomedicine and Biotechnology
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Figure 1: Th1, Th2, and Th17 diﬀerentiation. (Left) A tradi-
tional Th1 and Th2 diﬀerentiation model. Th1 population pro-
ducing IFN-γ versus Th2 population producing IL-4 diﬀerentiate
in a mutually exclusive manner. (Right) A new Th diﬀerentiation
model. Additional population producing IL-17 (but producing nei-
ther IFN-γ nor IL-4) also diﬀerentiates from the same precursor
cells.
production and Th1 development, whereas IL-4 binding to
the IL-4 receptor promotes IL-4 production and Th2 devel-
opment [6]. Developments of Th1 and Th2 are mutually ex-
clusive and diﬀerentiation of one suppresses that of the other
by various mechanisms. In addition to these two subsets, re-
cent lines of evidence have shown that there is another Th
subset, called Th17 or ThIL-17 [7–9]( Figure 1). Th17 cells
produce IL-17 for induction of various inﬂammatory re-
sponses and for defense against some pathogens [10, 11].
The diﬀerentiation of Th17 cells requires IL-6 plus TGF-β
for commitment and IL-23 for development, while other cy-
tokines such as IL-1 and TNF-α also support the develop-
ment of Th17 [12–14].
IL-12wasoriginallyidentiﬁedasapotentinducerofIFN-
γ production by T, NK, and other types of lymphocytes and
was shown later to be a potent inducer of Th1 diﬀerenti-
ation of CD4+ T cells [15]. Until recently, IL-12 has been
the only known heterodimeric cytokine, composed of two
subunits, p35 and p40. The p35 subunit is homologous to
IL-6 and G-CSF with a four-α-helix bundle structure, while
the p40 subunit is homologous to the extracellular portion
of IL-6Rα and related cytokine receptors. Thus, it was pro-
posed that IL-12 evolved from a cytokine of the IL-6 family,
which is covalently bound to the extracellular portion of its
primordial α chain receptor [15]. Recently, IL-23 and IL-27
were identiﬁed as heterodimeric cytokines functionally and
structurallyrelated to IL-12 [16, 17](see[18,19] for review).
Now along with two other cytokines, CLC/soluble CNTFR
and CLC/CLF-1, IL-12, IL-23, and IL-27 compose a family of
heterodimeric cytokines [18, 20]. IL-23, a heterodimeric cy-
tokine composed of the IL-12p40 subunit and the IL-12p35-
related molecule p19, preferentially acts on memory Th1
CD4+ T cells for their proliferation [17], although IL-23 has
recently been shown to promote Th17 diﬀerentiation. IL-27,
another heterodimeric cytokine composed of the IL-12p40-
related protein EBI-3 [21] plus the IL-12p35-related pro-
tein p28, acts on na¨ ıve CD4+ T cells to induce the expres-
sion of the IL-12Rβ2 gene and make the cells responsive to
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Figure 2: Diﬀerential roles and diﬀerential requirement of IL-12
family members during the time course of Th1 development (APC,
antigen presenting cells; Th1eﬀ,e ﬀector Th1 cells; Th1mem, mem-
ory Th1 cells).
IL-12. While IL-12 is the most potent inducer of Th1 diﬀer-
entiation and IFN-γ production acting on eﬀector Th1 cells,
chronologically diﬀerential roles and diﬀerential usage of IL-
12, IL-23, and IL-27 have been proposed. First, IL-27 com-
mits na¨ ıve CD4+ Tc e l l st od i ﬀerentiate into Th1 cells by in-
ducing IL-12Rβ2, then IL-12 acts on committed eﬀector Th1
cells for IFN-γ production, followed by IL-23 mediating the
proliferation of memory Th1 cells [17]( Figure 2). While the
Th1 immune response is pivotal for the host defense against
pathogens including some bacteria and parasites such as Lis-
teria monocytogenes, Mycobacterium tuberculosis,a n dL. ma-
jor (reviewed by Romani et al. in [22]), as well as against tu-
mors [23], excess of Th1 responses may cause some autoim-
mune diseases including rheumatoid arthritis and multiple
sclerosis [24, 25]. It is of note that recent lines of evidence
haveshownthatsomeofthese“Th1-mediated”autoimmune
diseasesareactuallymediatedbyIL-23-drivenTh17cellpop-
ulations but not by IL-12-driven Th1 cell populations, as has
been shown for experimental autoimmune encephalomyeli-
tis, an experimental model for multiple sclerosis [7, 8] (see
also [26, 27] for review). Nonetheless, proper initiation, re-
inforcement, and maintenance of the Th1 response seems to
be ensured, and at the same time tightly regulated by related,
but distinct, cytokines [28].
3. IL-27 AND ITS RECEPTOR, WSX-1, FOR
Th1 DIFFERENTIATION
Sprecher et al. cloned an orphan cytokine receptor and
named it WSX-1 (what is now called IL-27R α chain; also
known as TCCR) after the WSXWS motif, a characteristic
feature of cytokine receptors, in its extracytoplasmic portionHiroki Yoshida et al. 3
Table 1: Responses of IL-27/IL-27R-deﬁcient mice to parasitic infection.
Mouse genotype Pathogen Helper T cell response Outcome Reference
WSX-1−/− Leishmania major Initial Th1 impaired Susceptibility to infection,
normal Th1 at later phase [33]
WSX-1−/− Trypanosoma cruzi Th1, Th2, and
Th17 enhanced
Increased hepatic immunopathology
due to cytokine production [45]
WSX-1−/− Toxoplasma gondii (acute) IFN-γ high
Proliferation high Increased hepatic immunopathology [46]
WSX-1−/−(a) Leishmania donovani Th1 enhanced Increased hepatic immunopathology [47]
WSX-1−/− Toxoplasma gondii (chronic) Th17 enhanced Exacerbated encephalitis [63]
EBI-3−/− Leishmania major Initial Th1 impaired Susceptibility to infection,
enhanced Th1 at later phase [34]
WSX-1−/− Trichuris muris Th2 enhanced Enhanced clearance [35, 36]
(a)TCCR (another name for WSX-1)-deﬁcient mice generated by Chen et al. [32].
[29]. WSX-1 binds to the gp130 (of IL-6R) to conform to
a fully functional IL-27 receptor complex, downstream of
which, STAT1 and STAT3 are activated by ligand binding
[30, 31]. Although the function of WSX-1 was not clear in
the original cloning paper, two groups including ours inde-
pendently generated strains of mice with WSX-1 (or TCCR)
gene disruption and demonstrated that WSX-1 is critical for
induction of Th1 responses and IFN-γ production. Chen et
al. [32] demonstrated that WSX-1−/− mice showed impaired
IFN-γ production and remarkable susceptibility to L. mono-
cytogenes. In the report by Yoshida et al. [33], an impair-
ment of Th1 development and IFN-γ production was also
demonstrated in WSX-1−/− mice infected with L. major.I n -
terestingly, impaired production of IFN-γ as only observed
at early phases of L. major infection, and the IFN-γ produc-
tion in WSX-1−/− mice was restored to the wild-type level at
later phases of infection. In accordance with this “in vivo”
observation, T cells from WSX-1−/− mice produced much
lessIFN-γ thanwild-typecellsduringprimarystimulationin
the presence of IL-12 for Th1 diﬀerentiation, while fully dif-
ferentiated WSX-1−/− Th1 cells produced a comparable level
of IFN-γ upon secondary stimulation. These data, both “in
vivo” and “in vitro,” indicated that WSX-1 is required for the
initial mounting of the Th1 response by na¨ ıve CD4+ T cells,
but its role is later mitigated presumably by the IL-12 system
in fully activated and diﬀerentiated Th1 cells. The impor-
tance of WSX-1 in Th1 diﬀerentiation was further substanti-
atedbythediscoveryofIL-27,aligandforWSX-1,asanother
Th1-inducing composite cytokine [16]. Early expression of
p28, a component of IL-27, prior to that of IL-12 compo-
nents,byactivateddendriticcellsalsosupportedtheideathat
IL-27 was involved in the early phase of Th1 diﬀerentiation
[16]. A report on the role of EBI-3, a subunit of IL-27, in
which EBI-3-deﬁcient mice showed susceptibility to L. ma-
jor infection with impaired Th1 response also supported the
importance of IL-27/WSX-1 in Th1 diﬀerentiation [34]. (See
Table 1 for comparison.)
While resistance against L. major exclusively depends on
proper Th1 responses, expulsion of Trichuris muris,ag a s -
trointestinal nematode from digestive canals largely depends
on Th2 responses. In our recent T. muris infection exper-
iments [35, 36], WSX-1−/− mice successfully expelled the
worm and failed to harbor chronic infection in contrast to
wild-type mice. WSX-1−/− lymphocytes produced signiﬁ-
cantly less IFN-γ and much more IL-4 and IL-13 than wild-
type cells in response to the worm antigen, reiterating that
WSX-1 is important for the initial mounting of proper Th1
responses during infection. Another interpretation of the re-
sults, however, is also possible for the impairment of Th1 re-
sponses against L. major and T. muris infection. (See below
in the following section.)
The molecular basis for the Th1-initiating property of
IL-27/WSX-1 was then elucidated [37]. STAT1 was shown
to bind to the cytoplasmic portion of WSX-1 in a tyrosine
phosphorylation-dependent manner and following STAT1
activation by IL-27 stimulation, T-bet was activated to pro-
mote Th1 diﬀerentiation. The binding of STAT1 to WSX-1
is reasonable, since WSX-1 has pYEKHF motif at the con-
served tyrosine residue, which shares amino acid similarities
to the STAT1 docking site of the IFN-γR, pYDKPH [38, 39].
STAT1 activation per se by IL-27 stimulation has no direct
eﬀect on IFN-γ production but STAT1-mediated T-bet acti-
vation followed by IL-12Rβ2 expression was one of the crit-
ical events for Th1 diﬀerentiation. Other mechanisms, such
as MHC class I augmentation, ICAM-1 expression, and sup-
pression of the expression of GATA-3, a transcription factor
pivotal for Th2 diﬀerentiation, were also involved for IL-27-
mediated Th1 diﬀerentiation [40–42]. It is now clear that the
molecular basis of IL-27/WSX-1-mediated Th1 initiation is
the induction of T-bet, which is reminiscent of the ﬁnding
thattheIFN-γ stimulationofcellsinducesT-betinaSTAT-1-
dependent fashion[43,44].Interestingly, evenintheabsence
of WSX-1, T-bet was induced at later time points after T
cell stimulation (our unpublished observation), presumably4 Journal of Biomedicine and Biotechnology
due to the small amount of IFN-γ produced or a STAT1-
independent mechanism yet to be determined [40]. This de-
layedinductionofT-betmayexplaintherestorationofIFN-γ
production and IL-12 responsiveness of WSX-1−/− Tc e l l sa t
later time points [45].
4. SUPPRESSION OF INFLAMMATORY
RESPONSES BY IL-27
In sharp contrast to the ﬁnding that IL-27 is important
for Th1 promotion, recent reports also demonstrated that
IL-27 plays a regulatory role in immune responses. WSX-
1−/− mice, when infected with T. cruzi or Toxoplasma gondii,
showed remarkable sensitivity to the infection [45, 46].
This high sensitivity to infection was not due to impaired
Th1 diﬀerentiation or IFN-γ production. Unexpectedly, over
production of various proinﬂammatory cytokines including
INF-γ,T N F - α, and IL-6 was observed in infected WSX-1−/−
mice, followed by lethal liver necrosis. Rosas et al. also re-
ported severe liver immunopathology in TCCR- (another
name for WSX-1) deﬁcient mice infected with Leishmania
donovani [47]. Sources of the cytokines were not limited to
T cells, but other types of cells such as NK/NKT cells and
macrophages also produced various cytokines. In addition,
WSX-1−/− CD4+ T cells were more activated than wild-type
cells in terms of cell cycle progression and expression of sur-
face activation makers [46]. Similarly, WSX-1−/− NKT cells
produced more of the proinﬂammatory cytokines, inducing
lethal liver damages in Con A-induced liver damage exper-
iment, which is an experimental model of viral or autoim-
mune hepatitis [48]. Although the development of NKT cells
were normal in WSX-1−/− mice, these WSX-1−/− NKT cells
produced more IFN-γ and IL-4 than wild-type NKT cells in
response to Con A or α-galactosyl ceramide stimulation in
vitro. When infected with M. tuberculosis, WSX-1−/− mice
also suﬀered from liver damages and cachexia due to over
production of inﬂammatory cytokines, such as TNF-α [49].
Interestingly, WSX-1−/− mice harbored signiﬁcantly lower
bacterial loads over wild-type mice due to higher amounts
of TNF-α and IFN-γ. These results remind us of the fact that
immunity against pathogens is a double-edged sword; it kills
the pathogens in one way but may hurt the host in another
way. Beside the observations described above, IL-27 actu-
ally suppressed cytokine production-activated CD4+ Tc e l l s
[31]invitro.IL-27alsosuppressedcytokineproductionsuch
as TNF-α and IL-12 by macrophages [49, 50]. In these re-
ports, IL-27 stimulation induced STAT3 activation and con-
currently suppressed cytokine production by LPS-stimulated
macrophages. Interestingly, IL-27 stimulation appeared less
eﬀective in macrophage suppression than IL-4 or IL-10.
Stimulation of macrophages with IL-4, IL-10, or IL-27 re-
sulted in diﬀerential gene induction, suggesting distinct sup-
pression mechanisms by respective cytokines [50]. Wirtz et
al. alsoreported the suppressive eﬀectof IL-27 onmonocytes
and granulocytes reactive oxygen intermediate (ROI) pro-
duction [51]. Administration of recombinant IL-27 to mice
in the septic peritonitis model resulted in higher mortality
thanuntreatedmiceduetoreducedbacterialclearancebythe
down regulation of granulocyte/monocyte function. Collec-
tively, these data revealed the novel role of IL-27/WSX-1 as
an attenuator of proinﬂammatory cytokine production and
cell activation of T cells as well as macrophages, to suppress
excess of inﬂammation and/or to cease immune responses.
In this regard, a distinct (but not mutually exclusive) hy-
pothesis on the impairment of Th1 responses in the WSX-
1−/− mice should be described. Artis et al. reported an over-
production of IL-4 in L. major-infected WSX-1−/− mice and
suggested that the overproduction of Th2 cytokines at early
phases of infection reciprocally suppressed the following
IFN-γ production and Th1 development [52]. Similarly, Ar-
tis et al. also reported that upregulation of Th2 responses
is independent from Th1 impairment in T. muris-infected
WSX-1−/− mice, claiming that primary role of IL-27 is the
suppression of immune responses (including Th2 responses)
but may not be the induction of Th1 diﬀerentiation (see [36]
andseereviewbyHunteretal.[53]).Althoughreconciliation
of the two seemingly conﬂicting ideas awaits further analyses
of the role of IL-27 in various settings, a recent report by our
groupshedslightonthisissue[31].Inthisreport,Yoshimura
et al. demonstrated that IL-27 acts on na¨ ıve T cells for IFN-γ
productionwhilethesamecytokinesuppressescytokinepro-
duction by aﬀecting fully activated cells. Therefore, the acti-
vation status of the cells may be the key determinant for the
eﬀects of IL-27.
The underlying mechanisms for this immune/inﬂam-
mation suppression by IL-27 are not fully elucidated. It has
been reported that IL-27 inhibited IL-2 production by CD4+
T cells thereby regulating an excess of cell activation [54, 55].
In WSX-1−/− mice (or cells), however, not only IL-2 produc-
tion but also the production of various types of cytokines
were augmented [45]. Additionally, the source of cytokine
production was not limited to CD4+ T cells, but other types
ofcellswerealsoaﬀectedbyWSX-1deﬁciency.IL-10produc-
tion was unexpectedly augmented similarly by WSX-1 de-
ﬁciency [45, 46] and the so-called regulatory T cells (Treg)
did not appear to be aﬀected by the receptor deﬁciency [56].
A mechanism that collectively regulates cytokine production
and/or cell activation should be taken into consideration.
5. Th17 AND IL-23 VERSUS IL-27
IL-23, another IL-12 cytokine family member, has recently
been described to induce the diﬀerentiation of a new sub-
set of Th cells, namely, Th17 [7, 8, 57]. Th17 cells diﬀer-
entiate from the same precursor cells as Th1 or Th2 cells,
during which IL-6 and TGF-β plus IL-23 are required. Th17
cells exclusively produce IL-17, an inﬂammatogenic cytokine
[58], but not IFN-γ or IL-4. IL-17 plays a pivotal role in
the induction of some inﬂammatory diseases such as ex-
perimental autoimmune encephalomyelitis [7, 59], inﬂam-
matory bowel diseases [60], and rheumatoid arthritis [61].
It has also been reported that IL-17 is critically involved in
some forms of infection, either by induction of inﬂamma-
tory cytokines such as TNF-α or by recruiting neutrophils
[10, 11], although not much is known about the role of IL-
17 on the defense against parasite infection at this momentHiroki Yoshida et al. 5
Th17
Anti-inﬂammation
Inﬂammation
Na¨ ıve T cells Th2
IL-4 IL-23
IL-12
IL-27
Th1
Figure 3: Multidimensional regulation of Th cell diﬀerentiation by
IL-12 family members plus IL-4. Solid arrows show Th1, Th2, and
Th17 diﬀerentiation axes induced by IL-12, IL-4, and IL-23, respec-
tively, plus anti-inﬂammatory axis by IL-27. Dashed arrows show
roles of IL-27 and IL-23 for Th1 induction. IL-12 cytokine family
members are underlined.
[62]. A recent report by Stumhofer et al. revealed an in-
triguing function of IL-27 in view of its immune suppression
[63]. In their report, Stumhofer et al. revealed that WSX-1-
deﬁcient mice chronically infected with T. gondii developed
severe neuroinﬂammation with a prominent IL-17 response.
We also reported that IL-27 receptor-deﬁcient mice infected
with T. cruzi produced more IL-17 in the sera than wild-type
mice [31]. Although the precise role of IL-17 in pathogen-
esis of encephalomyelitis and infection-induced inﬂamma-
tion has yet to be elucidated, therefore, IL-17 produced in
response to pathogens appears at least partially responsible
for tissue damages induced by inﬂammation. In both reports
and one by Batten et al. [56], IL-27 suppressed the develop-
ment of Th17. It is interesting that IL-23, a member of IL-
12 cytokine family, induces the development of Th17 for the
induction of inﬂammatory responses while IL-27, another
member of the family, inhibits the Th17 diﬀerentiation to
suppress inﬂammation (Figure 3). Availability of IL-12 fam-
ily cytokines plus other cytokines, such as IL-6 and TGF-β in
the surrounding milieu, may determine the direction of im-
mune responses toward either augmentation or regression.
IL-27 thus may be a potential target for treating inﬂamma-
tory diseases of infection and autoimmune origin mediated
by IL-17. The molecular basis for the inhibition of Th17 dif-
ferentiationisstillunclear.WhileStumhoferetal.andBatten
et al. showed that the IL-27-meidated Th17 inhibition is de-
pendent on STAT1 by taking advantage of STAT1-deﬁcient
mice, we demonstrated the requirement of STAT3 for this
inhibition by using STAT3-deﬁcient T cells. Although fur-
ther elucidation of the molecular mechanisms for the IL-27-
mediated Th17 inhibition is required, it would be reasonable
to assume that appropriate balance of STAT1 and STAT3 ac-
tivation downstream of the receptor determines the function
of IL-27 signaling, as implicated by a transgenic mice study
[64]orbyexaminationofsurfaceWSX-1expressiononna¨ ıve
and activated T cells [65].
6. FUTURE PROSPECT
Since its discovery, IL-12 has been the only Th1-promoting
cytokine for more than 10 years. It has been well recognized
that the balance between IL-12-induced Th1 responses ver-
susIL-4-mediatedTh2responsesdeterminestheimmunere-
sponses against pathogens. Discoveries of two other IL-12-
related cytokines along with the new Th cell population have
beenchallengingandchangingtheparadigm.Asdiscussedin
this review, the IL-12 family members play diﬀerential roles
in induction and maintenance of Th1 responses during the
time course of infection/immune responses. IL-27 is critical
i nt h ec o m m i t m e n to fT hp r e c u r s o rc e l l st o w a r d sT h 1d i ﬀer-
entiation and IL-27 receptor deﬁciency resulted in impaired
Th1 responses with high susceptibility to L. major infection.
While having some overlapping functions, the members of
the family also have distinct roles during immune responses.
IL-23, one of the new comers to the family, augments in-
ﬂammationbyinductionofTh17cells,whileIL-27,theother
newcomer,attenuatesinﬂammationbysuppressingcytokine
production. These ﬁndings remind us of the intriguing fact
that immune responses are elaborately regulated along the
timecourseofinfectiontoﬁghtthedangerouspathogensand
to simultaneously avoid hazardous damage to oneself. In this
view, the multifaceted role of IL-27 is particularly notable.
Although the induction of Th1 diﬀerentiation and suppres-
sion of cytokine production are seemingly conﬂicting, these
distinct functions are quite reasonable when diﬀerent tar-
get cells (na¨ ıve versus activated) and/or diﬀerent time points
(early versus late phase of activation) are taken into consid-
eration. It would be premature to discuss the possibility of
using IL-27 for treatment of disease because of the complex-
ity of its role. However, further elucidation of the molecu-
lar mechanisms underlying the two distinct functions of IL-
27 signaling as well as clariﬁcation of the situations where
the two roles are diﬀerentially used will ensure that it will
eventually be possible to use IL-27 either to reinforce de-
fense against infectious agents or to treat infection-induced
immunopathology and inﬂammatory diseases.
ACKNOWLEDGMENTS
The authors would like to thank members of the “Project W”
for helpful discussion. The studies described in this review
were supported in part by grants from the Ministry of Edu-
cation,Science,Technology,Sports,andCultureofJapan(H.
Yoshida, S. Hamano, and Y. Yoshiyuki), from the Japan Re-
search Foundation for Clinical Pharmacology (H. Miyazaki),
from the Sumitomo Foundation, a grant for Basic Science
Research Projects (H. Yoshida), from the Naito Foundation
(Y. Yoshida), and from the Takeda Science Foundation (H.
Yoshida). S. Wang is a recipient of the Japan Society for the
Promotion of Science (JSPS) postdoctoral fellowship for for-
eign researchers.
REFERENCES
[1] D. Sacks and N. Noben-Trauth, “The immunology of suscep-
tibility and resistance to Leishmania major in mice,” Nature
Reviews Immunology, vol. 2, no. 11, pp. 845–858, 2002.6 Journal of Biomedicine and Biotechnology
[ 2 ]E .v a nd eV o s s e ,M .A .H o e v e ,a n dT .H .M .O t t e n h o ﬀ,“ H u -
man genetics of intracellular infectious diseases: molecular
and cellular immunity against mycobacteria and salmonellae,”
Lancet Infectious Diseases, vol. 4, no. 12, pp. 739–749, 2004.
[3] T. R. Mosmann and S. Sad, “The expanding universe of T-
cell subsets: Th1, Th2 and more,” Immunology Today, vol. 17,
no. 3, pp. 138–146, 1996.
[4] S. L. Reiner and R. M. Locksley, “The regulation of immunity
to Leishmania major,” Annual Review of Immunology, vol. 13,
pp. 151–177, 1995.
[5] F. D. Finkelman, T. Shea-Donohue, J. Goldhill, et al., “Cy-
tokine regulation of host defense against parasitic gastroin-
testinal nematodes: lessons from studies with rodent models,”
Annual Review of Immunology, vol. 15, pp. 505–533, 1997.
[6] K. M. Murphy, W. Ouyang, J. D. Farrar, et al., “Signaling and
transcription in T helper development,” Annual Review of Im-
munology, vol. 18, pp. 451–494, 2000.
[7] C. L. Langrish, Y. Chen, W. M. Blumenschein, et al., “IL-
23 drives a pathogenic T cell population that induces au-
toimmune inﬂammation,” Journal of Experimental Medicine,
vol. 201, no. 2, pp. 233–240, 2005.
[8] H. Park, Z. Li, X. O. Yang, et al., “A distinct lineage of CD4
T cells regulates tissue inﬂammation by producing interleukin
17,” Nature Immunology, vol. 6, no. 11, pp. 1133–1141, 2005.
[9] L. E. Harrington, R. D. Hatton, P. R. Mangan, et al., “Inter-
leukin 17-producing CD4+ eﬀector T cells develop via a lin-
eage distinct from the T helper type 1 and 2 lineages,” Nature
Immunology, vol. 6, no. 11, pp. 1123–1132, 2005.
[ 1 0 ]A .C .P a t e r a ,L .P e s n i c a k ,J .B e r t i n ,a n dJ .I .C o h e n ,“ I n t e r -
leukin 17 modulates the immune response to vaccinia virus
infection,” Virology, vol. 299, no. 1, pp. 56–63, 2002.
[11] P. Ye, P. B. Garvey, P. Zhang, et al., “Interleukin-17 and lung
host defense against Klebsiella pneumoniae infection,” Amer-
ican Journal of Respiratory Cell and Molecular Biology, vol. 25,
no. 3, pp. 335–340, 2001.
[12] E.Bettelli,Y.Carrier,W.Gao,etal.,“Reciprocaldevelopmental
pathways for the generation of pathogenic eﬀector TH17 and
regulatory T cells,” Nature, vol. 441, no. 7090, pp. 235–238,
2006.
[13] M.V eldhoen,R.J .H ocking,C.J .A tkins,R.M.Locksley ,andB.
Stockinger, “TGFβ in the context of an inﬂammatory cytokine
milieu supports de novo diﬀerentiation of IL-17-producing T
cells,” Immunity, vol. 24, no. 2, pp. 179–189, 2006.
[14] C. Sutton, C. Brereton, B. Keogh, K. H. G. Mills, and E. C.
Lavelle, “A crucial role for interleukin (IL)-1 in the induc-
tion of IL-17-producing T cells that mediate autoimmune en-
cephalomyelitis,” Journal of Experimental Medicine, vol. 203,
no. 7, pp. 1685–1691, 2006.
[15] G. Trinchieri, “Interleukin-12 and the regulation of innate re-
sistanceandadaptiveimmunity,”NatureReviewsImmunology,
vol. 3, no. 2, pp. 133–146, 2003.
[16] S. Pﬂanz, J. C. Timans, J. Cheung, et al., “IL-27, a het-
erodimeric cytokine composed of EBI3 and p28 protein, in-
duces proliferation of na¨ ıve CD4+ Tc e l l s , ”Immunity, vol. 16,
no. 6, pp. 779–790, 2002.
[17] B. Oppmann, R. Lesley, B. Blom, et al., “Novel p19 protein
engages IL-12p40 to form a cytokine, IL-23, with biological
activities similar as well as distinct from IL-12,” Immunity,
vol. 13, no. 5, pp. 715–725, 2000.
[18] A. V. Villarino, E. Huang, and C. A. Hunter, “Understanding
the pro- and anti-inﬂammatory properties of IL-27,” Journal
of Immunology, vol. 173, no. 2, pp. 715–720, 2004.
[19] C. A. Hunter, “New IL-12-family members: IL-23 and IL-27,
cytokineswithdivergentfunctions,”NatureReviewsImmunol-
ogy, vol. 5, no. 7, pp. 521–531, 2005.
[20] G. Trinchieri, S. Pﬂanz, and R. A. Kastelein, “The IL-12 family
of heterodimeric cytokines: new players in the regulation of T
cell responses,” Immunity, vol. 19, no. 5, pp. 641–644, 2003.
[21] O. Devergne, M. Hummel, H. Koeppen, et al., “A novel
interleukin-12 p40-related protein induced by latent Epstein-
Barr virus infection in B lymphocytes,” Journal of Virology,
vol. 70, no. 2, pp. 1143–1153, 1996.
[22] L. Romani, P. Puccetti, and F. Bistoni, “Interleukin-12 in in-
fectious diseases,” Clinical Microbiology Reviews, vol. 10, no. 4,
pp. 611–636, 1997.
[23] M. P. Colombo and G. Trinchieri, “Interleukin-12 in anti-
tumor immunity and immunotherapy,” Cytokine and Growth
Factor Reviews, vol. 13, no. 2, pp. 155–168, 2002.
[24] B. Y. Kang and T. S. Kim, “Targeting cytokines of the
interleukin-12 family in autoimmunity,” Current Medicinal
Chemistry, vol. 13, no. 10, pp. 1149–1156, 2006.
[25] B. Skurkovich and S. Skurkovich, “Inhibition of IFN-γ as a
method of treatment of various autoimmune diseases, includ-
ing skin diseases,” Ernst Schering Research Foundation Work-
shop, no. 56, pp. 1–27, 2006.
[26] Y. Iwakura and H. Ishigame, “The IL-23/IL-17 axis in inﬂam-
mation,” Journal of Clinical Investigation, vol. 116, no. 5, pp.
1218–1222, 2006.
[27] B. S. McKenzie, R. A. Kastelein, and D. J. Cua, “Understand-
ing the IL-23-IL-17 immune pathway,” Trends in Immunology,
vol. 27, no. 1, pp. 17–23, 2006.
[28] D. S. Robinson and A. O’Garra, “Further checkpoints in Th1
development,” Immunity, vol. 16, no. 6, pp. 755–758, 2002.
[29] C. A. Sprecher, F. J. Grant, J. W. Baumgartner, et al., “Cloning
and characterization of a novel class I cytokine receptor,” Bio-
chemical and Biophysical Research Communications, vol. 246,
no. 1, pp. 82–90, 1998.
[30] S. Pﬂanz, L. Hibbert, J. Mattson, et al., “WSX-1 and glycopro-
tein 130 constitute a signal-transducing receptor for IL-27,”
Journal of Immunology, vol. 172, no. 4, pp. 2225–2231, 2004.
[31] T.Yoshimura,A.Takeda,S.Hamano,etal.,“Two-sidedrolesof
IL-27: induction of Th1 diﬀerentiation on na¨ ıve CD4+ Tc e l l s
versus suppression of proinﬂammatory cytokine production
including IL-23-induced IL-17 on activated CD4+ Tc e l l sp a r -
tially through STAT3-dependent mechanism,” Journal of Im-
munology, vol. 177, no. 8, pp. 5377–5385, 2006.
[32] Q. Chen, N. Ghilardi, H. Wang, et al., “Development of Th1-
type immune responses requires the type I cytokine receptor
TCCR,” Nature, vol. 407, no. 6806, pp. 916–920, 2000.
[33] H. Yoshida, S. Hamano, G. Senaldi, et al., “WSX-1 is required
for the initiation of Th1 responses and resistance to L. major
infection,” Immunity, vol. 15, no. 4, pp. 569–578, 2001.
[34] S. Zahn, S. Wirtz, M. Birkenbach, R. S. Blumberg, M. F. Neu-
rath, and E. von Stebut, “Impaired Th1 responses in mice de-
ﬁcient in Epstein-Barr virus-induced gene 3 and challenged
with physiological doses of Leishmania major,” European Jour-
nal of Immunology, vol. 35, no. 4, pp. 1106–1112, 2005.
[35] A.J.Bancroft,N.E.Humphreys,J.J.Worthington,H.Yoshida,
and R. K. Grencis, “WSX-1: a key role in induction of
chronic intestinal nematode infection,” Journal of Immunol-
ogy, vol. 172, no. 12, pp. 7635–7641, 2004.
[36] D. Artis, A. Villarino, M. Silverman, et al., “The IL-27 receptor
(WSX-1) is an inhibitor of innate and adaptive elements of
type 2 immunity,” Journal of Immunology, vol. 173, no. 9, pp.
5626–5634, 2004.Hiroki Yoshida et al. 7
[37] A. Takeda, S. Hamano, A. Yamanaka, et al., “Cutting edge: role
of IL-27/WSX-1 signaling for induction of T-bet through ac-
tivation of STAT1 during initial Th1 commitment,” Journal of
Immunology, vol. 170, no. 10, pp. 4886–4890, 2003.
[ 3 8 ]M .A .F a r r a r ,J .D .C a m p b e l l ,a n dR .D .S c h r e i b e r ,“ I d e n t i ﬁ c a -
tion of a functionally important sequence in the C terminus of
theinterferon-γ receptor,”ProceedingsoftheNationalAcademy
of Sciences of the United States of America, vol. 89, no. 24, pp.
11706–11710, 1992.
[39] A. C. Greenlund, M. A. Farrar, B. L. Viviano, and R. D.
Schreiber, “Ligand-induced IFN(γ) receptor tyrosine phos-
phorylationcouplesthereceptortoitssignaltransductionsys-
tem(p91),”EMBOJournal,vol.13,no.7,pp.1591–1600,1994.
[40] S. Lucas, N. Ghilardi, J. Li, and F. J. de Sauvage, “IL-27 reg-
ulates IL-12 responsiveness of na¨ ıve CD4+ T cells through
STAT1-dependent and -independent mechanisms,” Proceed-
ings of the National Academy of Sciences of the United States
of America, vol. 100, no. 25, pp. 15047–15052, 2003.
[41] S. Kamiya, T. Owaki, N. Morishima, F. Fukai, J. Mizuguchi,
and T. Yoshimoto, “An indispensable role for STAT1 in IL-27-
induced T-bet expression but not proliferation of na¨ ıve CD4+
Tc e ll s , ”Journal of Immunology, vol. 173, no. 6, pp. 3871–3877,
2004.
[42] T. Owaki, M. Asakawa, N. Morishima, et al., “A role for IL-27
inearlyregulationofTh1diﬀerentiation,”JournalofImmunol-
ogy, vol. 175, no. 4, pp. 2191–2200, 2005.
[43] M. Afkarian, J. R. Sedy, J. Yang, et al., “T-bet is a STAT1-
induced regulator for IL-12R expression in na¨ ıve CD4+ T
cells,” Nature Immunology, vol. 3, no. 6, pp. 549–557, 2002.
[44] A. A. Lighvani, D. M. Frucht, D. Jankovic, et al., “T-bet is
rapidly induced by interferon-γ in lymphoid and myeloid
cells,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 98, no. 26, pp. 15137–15142,
2001.
[45] S.Hamano,K.Himeno,Y.Miyazaki,etal.,“WSX-1isrequired
for resistance to Trypanosoma cruzi infection by regulation
of proinﬂammatory cytokine production,” Immunity, vol. 19,
no. 5, pp. 657–667, 2003.
[46] A. Villarino, L. Hibbert, L. Lieberman, et al., “The IL-27R
(WSX-1) is required to suppress T cell hyperactivity during
infection,” Immunity, vol. 19, no. 5, pp. 645–655, 2003.
[47] L. E. Rosas, A. A. Satoskar, K. M. Roth, et al., “Interleukin-27R
(WSX-1/T-cell cytokine receptor) gene-deﬁcient mice display
enhanced resistance to Leishmania donovani infection but
develop severe liver immunopathology,” American Journal of
Pathology, vol. 168, no. 1, pp. 158–169, 2006.
[48] A. Yamanaka, S. Hamano, Y. Miyazaki, et al., “Hyperproduc-
tion of proinﬂammatory cytokines by WSX-1-deﬁcient NKT
cellsinconcanavalina-inducedhepatitis,”JournalofImmunol-
ogy, vol. 172, no. 6, pp. 3590–3596, 2004.
[49] C. H¨ olscher, A. H¨ o l s c h e r ,D .R¨ uckerl, et al., “The IL-27 recep-
tor chain WSX-1 diﬀerentially regulates antibacterial immu-
nity and survival during experimental tuberculosis,” Journal of
Immunology, vol. 174, no. 6, pp. 3534–3544, 2005.
[50] D. R¨ uckerl, M. Heßmann, T. Yoshimoto, S. Ehlers, and C.
H¨ olscher, “Alternatively activated macrophages express the IL-
27 receptor alpha chain WSX-1,” Immunobiology, vol. 211,
no. 6–8, pp. 427–436, 2006.
[51] S. Wirtz, I. Tubbe, P. R. Galle, et al., “Protection from lethal
septic peritonitis by neutralizing the biological function of in-
terleukin27,”JournalofExperimentalMedicine,vol.203,no.8,
pp. 1875–1881, 2006.
[52] D. Artis, L. M. Johnson, K. Joyce, et al., “Cutting edge: early
IL-4 production governs the requirement for IL-27-WSX-1
signaling in the development of protective Th1 cytokine re-
sponses following Leishmania major Infection,” Journal of Im-
munology, vol. 172, no. 8, pp. 4672–4675, 2004.
[53] C. A. Hunter, A. Villarino, D. Artis, and P. Scott, “The role of
IL-27 in the development of T-cell responses during parasitic
infections,” Immunological Reviews, vol. 202, no. 1, pp. 106–
114, 2004.
[54] T. Owaki, M. Asakawa, S. Kamiya, et al., “IL-27 suppresses
CD28-medicated IL-2 production through suppressor of cy-
tokine signaling 3,” Journal of Immunology, vol. 176, no. 5, pp.
2773–2780, 2006.
[55] A.V .V illarino ,J .S.Stumhofer ,C.J .M.Saris,R.A.K astelein,F .
J. de Sauvage, and C. A. Hunter, “IL-27 limits IL-2 production
during Th1 diﬀerentiation,” Journal of Immunology, vol. 176,
no. 1, pp. 237–247, 2006.
[56] M. Batten, J. Li, S. Yi, et al., “Interleukin 27 limits autoim-
mune encephalomyelitis by suppressing the development of
interleukin 17-producing T cells,” Nature Immunology, vol. 7,
no. 9, pp. 929–936, 2006.
[57] S. Aggarwal, N. Ghilardi, M.-H. Xie, F. J. de Sauvage, and A. L.
Gurney,“Interleukin-23promotesadistinctCD4Tcellactiva-
tion state characterized by the production of interleukin-17,”
Journal of Biological Chemistry, vol. 278, no. 3, pp. 1910–1914,
2003.
[58] J.K.KollsandA.Lind´ en,“Interleukin-17familymembersand
inﬂammation,” Immunity, vol. 21, no. 4, pp. 467–476, 2004.
[59] Y. Komiyama, S. Nakae, T. Matsuki, et al., “IL-17 plays an im-
portant role in the development of experimental autoimmune
encephalomyelitis,” Journal of Immunology, vol. 177, no. 1, pp.
566–573, 2006.
[60] D. Yen, J. Cheung, H. Scheerens, et al., “IL-23 is essential for
T cell-mediated colitis and promotes inﬂammation via IL-17
and IL-6,” Journal of Clinical Investigation, vol. 116, no. 5, pp.
1310–1316, 2006.
[61] K. Sato, A. Suematsu, K. Okamoto, et al., “Th17 functions as
an osteoclastogenic helper T cell subset that links T cell activa-
tion and bone destruction,” Journal of Experimental Medicine,
vol. 203, no. 12, pp. 2673–2682, 2006.
[62] M. N. Kelly, J. K. Kolls, K. Happel, et al., “Interteukin-
17/interleukin-17 receptor-mediated signaling is important
for generation of an optimal polymorphonuclear response
against Toxoplasma gondii infection,” Infection and Immunity,
vol. 73, no. 1, pp. 617–621, 2005.
[63] J. S. Stumhofer, A. Laurence, E. H. Wilson, et al., “Interleukin
27 negatively regulates the development of interleukin 17-
producing T helper cells during chronic inﬂammation of the
central nervous system,” Nature Immunology, vol. 7, no. 9, pp.
937–945, 2006.
[64] A. Takeda, S. Hamano, H. Shiraishi, et al., “WSX-1 over-
expression in CD4+ T cells leads to hyperproliferation and cy-
tokine hyperproduction in response to TCR stimulation,” In-
ternational Immunology, vol. 17, no. 7, pp. 889–897, 2005.
[65] A. V. Villarino, J. Larkin III, C. J. M. Saris, et al., “Positive and
negative regulation of the IL-27 receptor during lymphoid cell
activation,” Journal of Immunology, vol. 174, no. 12, pp. 7684–
7691, 2005.